Aligos Therapeutics, Inc. (ALGS)
5.76
-0.45
(-7.25%)
USD |
NASDAQ |
Sep 08, 16:00
6.40
+0.64
(+11.11%)
Pre-Market: 08:26
Aligos Therapeutics Enterprise Value : 9.005M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 9.005M |
| September 04, 2026 | 11.81M |
| September 03, 2026 | 11.87M |
| September 02, 2026 | 11.81M |
| September 01, 2026 | 11.06M |
| August 31, 2026 | 9.629M |
| August 28, 2026 | 16.18M |
| August 27, 2026 | 17.18M |
| August 26, 2026 | 19.92M |
| August 25, 2026 | 19.67M |
| August 24, 2026 | 16.30M |
| August 21, 2026 | 14.68M |
| August 20, 2026 | 13.25M |
| August 19, 2026 | 16.05M |
| August 18, 2026 | 15.24M |
| August 17, 2026 | 14.09M |
| August 14, 2026 | 16.05M |
| August 13, 2026 | 15.30M |
| August 12, 2026 | 16.74M |
| August 11, 2026 | 18.48M |
| August 10, 2026 | 20.79M |
| August 07, 2026 | 7.945M |
| August 06, 2026 | 7.446M |
| August 05, 2026 | 2.643M |
| August 04, 2026 | 2.706M |
| Date | Value |
|---|---|
| August 03, 2026 | 1.770M |
| July 31, 2026 | -0.5373M |
| July 30, 2026 | 0.024M |
| July 29, 2026 | -0.4126M |
| July 28, 2026 | -0.4126M |
| July 27, 2026 | -1.473M |
| July 24, 2026 | -1.473M |
| July 23, 2026 | 2.332M |
| July 22, 2026 | 5.200M |
| July 21, 2026 | 7.009M |
| July 20, 2026 | 6.011M |
| July 17, 2026 | 8.880M |
| July 16, 2026 | 8.943M |
| July 15, 2026 | 9.067M |
| July 14, 2026 | 11.16M |
| July 13, 2026 | 12.75M |
| July 10, 2026 | 14.37M |
| July 09, 2026 | 15.30M |
| July 08, 2026 | 15.05M |
| July 07, 2026 | 11.06M |
| July 06, 2026 | 9.566M |
| July 02, 2026 | 7.945M |
| July 01, 2026 | 7.072M |
| June 30, 2026 | 9.067M |
| June 29, 2026 | -17.13M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 581.29M |
| Amgen, Inc. | 255.86B |
| Anika Therapeutics, Inc. | 268.42M |
| BioCryst Pharmaceuticals, Inc. | 2.798B |
| Imunon, Inc. | 8.166M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.504M |
| Revenue (Quarterly) | 27.78M |
| Total Expenses (Quarterly) | 29.28M |
| EPS Diluted (Quarterly) | -0.1442 |
| Gross Profit Margin (Quarterly) | 99.08% |
| Profit Margin (Quarterly) | -5.41% |
| Earnings Yield | -127.0% |
| Normalized Earnings Yield | -130.92 |